Symbicort Dosing
For asthma in adults and adolescents ≥12 years, start with Symbicort 80/4.5 mcg (2 inhalations twice daily) and titrate to 160/4.5 mcg (2 inhalations twice daily) if needed; for children 6-11 years, use only Symbicort 80/4.5 mcg (2 inhalations twice daily); for COPD in adults, use Symbicort 160/4.5 mcg (2 inhalations twice daily). 1
Asthma Dosing
Adults and Adolescents (≥12 years)
The FDA-approved dosing is 2 inhalations twice daily (morning and evening, approximately 12 hours apart) 1. Two strength options exist:
- Symbicort 80/4.5 mcg: Starting dose for mild-to-moderate persistent asthma
- Symbicort 160/4.5 mcg: For moderate-to-severe persistent asthma or when 80/4.5 mcg provides inadequate control after 1-2 weeks
Maximum dose: Symbicort 160/4.5 mcg, 2 inhalations twice daily 1
The choice of starting strength should be based on asthma severity, current symptom control, and exacerbation risk 1. If patients don't respond adequately to 80/4.5 mcg after 1-2 weeks, step up to 160/4.5 mcg 1. This aligns with guideline recommendations that combination ICS-LABA therapy is preferred for moderate persistent asthma (step 3 care or higher) 2.
Children (6-11 years)
Only Symbicort 80/4.5 mcg is approved: 2 inhalations twice daily 1
The higher strength (160/4.5 mcg) is not FDA-approved for this age group. Guidelines support adding LABA to low-dose ICS as preferred therapy for moderate persistent asthma in children ≥5 years, though data in younger children are limited 3.
Children (<6 years)
Symbicort is not FDA-approved for children under 6 years 1. For this age group requiring ICS-LABA combination, alternative formulations with pediatric indications should be considered.
COPD Dosing
Adults Only
Symbicort 160/4.5 mcg, 2 inhalations twice daily 1
This is the only strength indicated for COPD maintenance treatment and exacerbation reduction 1. The 80/4.5 mcg strength is not approved for COPD. Research supports that this regimen improves lung function, reduces exacerbations, and enhances health status compared to placebo or monotherapy in patients with severe-to-very-severe COPD 4.
Administration Details
Critical administration points 1:
- Administer via oral inhalation only
- Rinse mouth with water after each use (without swallowing) to reduce oral candidiasis risk
- Prime before first use: Shake well for 5 seconds, release 2 test sprays into air away from face
- Re-prime if unused >7 days or dropped: Same priming procedure
- Use short-acting beta-agonist (not additional Symbicort) for acute symptom relief between doses
Important Dosing Limitations
Do not exceed 2 inhalations twice daily of the prescribed strength 1. Higher doses increase adverse effect risk, particularly with formoterol. Patients should never use additional LABA medications while on Symbicort 1.
Onset of action: Improvement can occur within 15 minutes, but maximum benefit may require 2 weeks or longer 1. If control remains inadequate after appropriate trial:
- Consider stepping up to higher strength (asthma)
- Add additional ICS
- Consider oral corticosteroids for severe cases
- Re-evaluate diagnosis and adherence 1
Clinical Context
The evidence strongly supports that ICS-LABA combinations like Symbicort are more effective than ICS monotherapy for preventing exacerbations and improving asthma control in moderate-to-severe persistent asthma 2, 5. However, LABAs should never be used as monotherapy for asthma due to increased risk of severe exacerbations and death 2, 6, 1.
For COPD, the combination therapy reduces exacerbations more effectively than bronchodilator monotherapy, though pneumonia risk with ICS use requires monitoring 7, 4.